The DOI matches its Crossref record; 133 of the 133 references it cites were found in a registry or an index.
Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease
Open accessAbstract
BACKGROUND: Alzheimer's disease (AD) is the most common form of dementia. The incidence of AD rises exponentially with age and its prevalence will increase significantly worldwide in the next few decades. Inflammatory processes have been suspected in the pathogenesis of the disease. OBJECTIVES: To review the efficacy and side effects of aspirin, steroidal and non-steroidal anti-inflammatory drugs (NSAIDs) in the treatment of AD, compared to placebo. SEARCH METHODS: We searched ALOIS: the Cochrane Dementia and Cognitive Improvement Group's Specialized Register on 12 April 2011 using the terms: aspirin OR "cyclooxygenase 2 inhibitor" OR aceclofenac OR acemetacin OR betamethasone OR celecoxib OR cortisone OR deflazacort OR dexamethasone OR dexibruprofen OR dexketoprofen OR diclofenac sodium OR diflunisal OR diflusinal OR etodolac OR etoricoxib OR fenbufen OR fenoprofen OR flurbiprofen OR hydrocortisone OR ibuprofen OR indometacin OR indomethacin OR ketoprofen OR lumiracoxib OR mefenamic OR meloxicam OR methylprednisolone OR nabumetone OR naproxen OR nimesulide OR "anti-inflammatory" OR prednisone OR piroxicam OR sulindac OR tenoxicam OR tiaprofenic acid OR triamcinolone OR NSAIDS OR NSAID. ALOIS contains records of clinical trials identified from monthly searches of a number of major healthcare databases (including MEDLINE, EMBASE, PsycINFO, CINAHL, LILACS), numerous trial registries (including national, international and pharmacuetical registries) and grey literature sources. SELECTION CRITERIA: All randomised controlled trials assessing the efficacy of aspirin, steroidal and non-steroidal anti-inflammatory drugs in AD. DATA COLLECTION AND ANALYSIS: One author assessed risk of bias of each study and extracted data. A second author verified data selection. MAIN RESULTS: Our search identified 604 potentially relevant studies. Of these, 14 studies (15 interventions) were RCTs and met our inclusion criteria. The numbers of participants were 352, 138 and 1745 for aspirin, steroid and NSAIDs groups, respectively. One selected study comprised two separate interventions. Interventions assessed in these studies were grouped into four categories: aspirin (three interventions), steroids (one intervention), traditional NSAIDs (six interventions), and selective cyclooxygenase-2 (COX-2) inhibitors (five interventions). All studies were evaluated for internal validity using a risk of bias assessment tool. The risk of bias was low for five studies, high for seven studies, and unclear for two studies.There was no significant improvement in cognitive decline for aspirin, steroid, traditional NSAIDs and selective COX-2 inhibitors. Compared to controls, patients receiving aspirin experienced more bleeding while patients receiving steroid experienced more hyperglycaemia, abnormal lab results and face edema. Patients receiving NSAIDs experienced nausea, vomiting, elevated creatinine, elevated LFT and hypertension. A trend towards higher death rates was observed among patients treated with NSAIDS compared with placebo and this was somewhat higher for selective COX-2 inhibitors than for traditional NSAIDs. AUTHORS' CONCLUSIONS: Based on the studies carried out so far, the efficacy of aspirin, steroid and NSAIDs (traditional NSAIDs and COX-2 inhibitors) is not proven. Therefore, these drugs cannot be recommended for the treatment of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Glutamate neurotoxicity and diseases of the nervous system
CHOI, D. (1988) · Neuron · doi:10.1016/0896-6273(88)90162-6 · Cited by 7,972
Diagnostic and Statistical Manual of Mental Disorders
Sciacca, F., Knipe, H., & Sharma, R. (2020) · Radiopaedia.org · doi:10.53347/rid-80880 · Cited by 2,361
Alzheimer Disease in the US Population: Prevalence Estimates Using the 2000 Census
Hebert, L. E., Scherr, P. A., Bienias, J. L., Bennett, D. A., & Evans, D. A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.8.1119 · Cited by 2,168
Citron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A. Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I., & Selkoe, D. J. (1992) · Nature · doi:10.1038/360672a0 · Cited by 1,757
(2010) · Handbook of Disease Burdens and Quality of Life Measures · doi:10.1007/978-0-387-78665-0_6514 · Cited by 1,385
McGeer, P. L., Schulzer, M., & McGeer, E. G. (1996) · Neurology · doi:10.1212/wnl.47.2.425 · Cited by 1,367
Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease
in 't Veld, B. A., Ruitenberg, A., Hofman, A., Launer, L. J., van Duijn, C. M., Stijnen, T., Breteler, M. M. B., & Stricker, B. H. C. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010178 · Cited by 1,196
Risk of Alzheimer's disease and duration of NSAID use
Stewart, W. F., Kawas, C., Corrada, M., & Metter, E. J. (1997) · Neurology · doi:10.1212/wnl.48.3.626 · Cited by 1,132
Clinical trial of indomethacin in Alzheimer's disease
Rogers, J., Kirby, L. C., Hempelman, S. R., Berry, D. L., McGeer, P. L., Kaszniak, A. W., Zalinski, J., Cofield, M., Mansukhani, L., Willson, P., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1609 · Cited by 999
Research works printed but not linked: 27
- Zhou, 2004, Effectiveness of polydrug therapy for senile dementia, Chinese Journal of Clinical Rehabilitation, 8, 1214
- Aisen, 2008, Rofecoxib in patients with mild cognitive impairment: further analyses of data from a randomized, double-blind, trial, Current Alzheimer Research, 5, 73, 10.2174/156720508783884602 · DOI
- Aizen, 2005, Effect of non-steroidal anti-inflammatory drugs on natural killer cell activity in patients with dementia, The Israel Medical Association Journal, 7, 78
- Jeong, 2004, Therapeutic potentials of mefenamic acid for the treatment of Alzheimer's disease, Neurobiology of Aging, 25, S589, 10.1016/S0197-4580(04)81961-4 · doi:10.1016/s0197-4580(04)81961-4
- Laughlin, 2006, Efficacy and safety of MPC-7869 (R-flurbiprofen), a Selective AB42-Lowering Agent, in Alzheimer's disease (AD): results of a 12-month phase 2 trial and 1-year follow-on study, Journal of the American Geriatrics Society, 54, S7
- Leblhuber F Haller H Steiner K Fuchs D DHEA treatment of Alzheimer's disease: A randomized, double-blind, placebo-controlled trial Neurology 2004 1030 · DOI
- McIntyre, 2006, MPC-7869 - prostate cancer therapy - treatment of Alzheimer's dementia, Drugs of the Future, 31, 22
- Meinert, 2008, Triflusal versus aspirin for the prevention of stroke, Progress in Neurotherapeutics and Neuropsychopharmacology, 3, 13
- Nourhashemi, 1998, Non steroidal anti-inflammatory drugs in Alzheimer disease, Presse Medicale, 27, 25
- Pomara, 1985, Multiple, single-dose naltrexone administrations fail to effect overall cognitive functioning and plasma cortisol in individuals with probable Alzheimer's disease, Neurobiology of Aging, 6, 233, 10.1016/0197-4580(85)90055-7 · doi:10.1016/0197-4580(85)90055-7
- Sainati SM Ingram DM Talwalker S Geis GS Results of a double-blind, randomized, placebo-controlled study of celecoxib in the treatment of progression of Alzheimer's disease Proceedings of the 6th International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 Apr 5-8, Stockholm, Sweden 2000 180
- Simon, 1998, Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor - Efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects, Arthritis and Rheumatism, 41, 1591, 10.1002/1529-0131(199809)41:9<1591::AID-ART9>3.0.CO;2-J · doi:10.1002/1529-0131(199809)41:9<1591::aid-art9>3.0.co;2-j
- Solomon, 2008, Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis, Circulation, 117, 2104, 10.1161/CIRCULATIONAHA.108.764530 · DOI · Paper page
- Stevenson, 2004, A pharmacokinetic, pharmacodynamic, and safety study of celecoxib in subjects with probable Alzheimer's disease, Clinical Research and Regulatory Affairs, 21, 49, 10.1081/CRP-120030034 · DOI
- Stoppe, 1996, Prescribing practice with cognition enhancers in outpatient care: Are there differences regarding type of dementia? Results of a representation survey in lower Saxony, Germany, Pharmacopsychiatry, 29, 150, 10.1055/s-2007-979562 · doi:10.1055/s-2007-979562
- Tsartsalis, 2011, Non-cholinergic pharmacotherapy approaches to Alzheimer's disease: the use of non-steroidal anti-inflammatory drugs, CNS & Neurological Disorders-Drug Targets, 10, 133, 10.2174/187152711794488629 · doi:10.2174/187152711794488629
- Watson, 2004, Rosiglitazone preserves cognitive functions in patients with early Alzheimer's disease, Neurobiology of Aging, 25, 83, 10.1016/S0197-4580(04)80284-7 · doi:10.1016/s0197-4580(04)80284-7
- Wisloff, 1996, Effect of interferon on the health-related quality of life of multiple myeloma patients: results of a Nordic randomized trial comparing melphalan-prednisone to melphalan-prednisone + alpha-interferon. The Nordic Myeloma Study Group, British Journal of Haematology, 94, 324, 10.1046/j.1365-2141.1996.d01-1802.x · doi:10.1046/j.1365-2141.1996.d01-1802.x
- Wollheim, 2000, Selective Cox-2 inhibition in man - therapeutic breakthrough or cosmetic advance?, Rheumatology, 39, 935, 10.1093/rheumatology/39.9.935 · doi:10.1093/rheumatology/39.9.935
- Xia, 2007, Follow-up of a randomized, placebo-controlled trial of dexamethasone to decrease the duration of ventilator dependency in very low birth weight infants: neurodevelopmental outcomes at 4 to 11 years of age, Pediatrics, 120, 594, 10.1542/peds.2007-0486 · DOI
- Yaqub, 1999, New horizons in management of Alzheimer's disease, Saudi Medical Journal, 20, 671
- Zandi, 2005, Pharmacological strategies for prevention of Alzheimer's disease: the epidemiologic evidence, Research and Practice in Alzheimer's Disease, 10, 200
- Zaragoza, 2005, Attitude before COX-2 selective inhibitors, Revista De Investigacion Clinica, 57, 6
- Zhai, 2010, Efficacy observation of batroxobin for treatment of vascular cognitive impairment, Chinese Journal of Cerebrovascular Diseases, 7, 73
- Aisen, 1996, A pilot study of prednisone in Alzheimer's disease, Dementia, 7, 201
- World Health Organisation, 1992, The ICD-10 Classification of Mental and Behavioural disorders: clinical Descriptions and Diagnostic Guidelines
- Wilcock, 2006, Efficacy and safety of MPC-7869 (R-flurbiprofen), a selective Ab42-lowering agent, in Alzheimers disease (AD): Results of a 12-month phase 2 trial and 1-year follow-on study., Alzheimer and Dementia, 2, S81
Cited by
How neuroinflammation contributes to neurodegeneration
Ransohoff, R. M. (2016) · Science · doi:10.1126/science.aag2590 · Cited by 1,967
Neuroinflammation in Alzheimer's disease: current evidence and future directions
Calsolaro, V., & Edison, P. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.02.010 · Cited by 1,726
Fricker, M., Tolkovsky, A. M., Borutaite, V., Coleman, M., & Brown, G. C. (2018) · Physiological Reviews · doi:10.1152/physrev.00011.2017 · Cited by 1,108
Microglia polarization from M1 to M2 in neurodegenerative diseases
Guo, S., Wang, H., & Yin, Y. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.815347 · Cited by 920
Neuroinflammation: The role and consequences
Lyman, M., Lloyd, D. G., Ji, X., Vizcaychipi, M. P., & Ma, D. (2014) · Neuroscience Research · doi:10.1016/j.neures.2013.10.004 · Cited by 730
Alternatively activated microglia and macrophages in the central nervous system
Franco, R., & Fernández-Suárez, D. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.05.003 · Cited by 650
Drug treatments in Alzheimer’s disease
Briggs, R., Kennelly, S. P., & O’Neill, D. (2016) · Clinical Medicine · doi:10.7861/clinmedicine.16-3-247 · Cited by 571
Inflammation in neurodegenerative diseases—An update
Amor, S., Peferoen, L. A. N., Vogel, D. Y. S., Breur, M., van der Valk, P., Baker, D., & van Noort, J. M. (2014) · Immunology · doi:10.1111/imm.12233 · Cited by 550
Activation of microglia and astrocytes: a roadway to neuroinflammation and Alzheimer’s disease
Kaur, D., Sharma, V., & Deshmukh, R. (2019) · Inflammopharmacology · doi:10.1007/s10787-019-00580-x · Cited by 484
An early and late peak in microglial activation in Alzheimer’s disease trajectory
Fan, Z., Brooks, D. J., Okello, A., & Edison, P. (2017) · Brain · doi:10.1093/brain/aww349 · Cited by 424
Drug candidates in clinical trials for Alzheimer’s disease
Hung, S.-Y., & Fu, W.-M. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0355-7 · Cited by 420
Aspirin: a review of its neurobiological properties and therapeutic potential for mental illness
Berk, M., Dean, O., Drexhage, H., McNeil, J. J., Moylan, S., O'Neil, A., Davey, C. G., Sanna, L., & Maes, M. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-74 · Cited by 391
Targeting Tumor Necrosis Factor Alpha for Alzheimer’s Disease
Decourt, B., Lahiri, D. K., & Sabbagh, M. N. (2017) · Current Alzheimer Research · doi:10.2174/1567205013666160930110551 · Cited by 371
Review: Systemic inflammation andAlzheimer's disease
Holmes, C. (2013) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2012.01307.x · Cited by 356
Arai, Y., Martin-Ruiz, C. M., Takayama, M., Abe, Y., Takebayashi, T., Koyasu, S., Suematsu, M., Hirose, N., & von Zglinicki, T. (2015) · EBioMedicine · doi:10.1016/j.ebiom.2015.07.029 · Cited by 333
Skvarc, D. R., Berk, M., Byrne, L. K., Dean, O. M., Dodd, S., Lewis, M., Marriott, A., Moore, E. M., Morris, G., Page, R. S., et al. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.11.011 · Cited by 312
Drug repositioning for Alzheimer's disease
Corbett, A., Pickett, J., Burns, A., Corcoran, J., Dunnett, S. B., Edison, P., Hagan, J. J., Holmes, C., Jones, E., Katona, C., et al. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3869 · Cited by 301
Kaushal, V, Dye, R., Pakavathkumar, P., Foveau, B., Flores, J., Hyman, B., Ghetti, B., Koller, B. H., & LeBlanc, A. C. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2015.16 · Cited by 297
Andrieu, S., Coley, N., Lovestone, S., Aisen, P. S., & Vellas, B. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00153-2 · Cited by 293
Karran, E., & Hardy, J. (2014) · Annals of Neurology · doi:10.1002/ana.24188 · Cited by 275
Govindpani, K., McNamara, L. G., Smith, N. R., Vinnakota, C., Waldvogel, H. J., Faull, R. L., & Kwakowsky, A. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8050651 · Cited by 275
Salkovic-Petrisic, M., Knezovic, A., Hoyer, S., & Riederer, P. (2013) · Journal of Neural Transmission · doi:10.1007/s00702-012-0877-9 · Cited by 272
Current Research Therapeutic Strategies for Alzheimer’s Disease Treatment
Folch, J., Petrov, D., Ettcheto, M., Abad, S., Sánchez-López, E., García, M. L., Olloquequi, J., Beas-Zarate, C., Auladell, C., & Camins, A. (2016) · Neural Plasticity · doi:10.1155/2016/8501693 · Cited by 270
“If identified in individuals under 65 years of age, early-onset diagnosis is given (3–5%prevalence), with the rest of the cases referred to as a late-onset AD (95–97% prevalence) [3–7].”
BackgroundChami, L., & Checler, F. (2012) · Molecular Neurodegeneration · doi:10.1186/1750-1326-7-52 · Cited by 168
“Different therapeutic strategies aimed at reducing inflammation or oxidative damage in AD did not prove to be successfull so far [211,212].”
BackgroundLiu, X., Hao, W., Qin, Y., Decker, Y., Wang, X., Burkart, M., Schötz, K., Menger, M. D., Fassbender, K., & Liu, Y. (2015) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2015.01.011 · Cited by 149
Drug development for alzheimer’s disease: Microglia induced neuroinflammation as a target
Dong, Y., Li, X., Cheng, J., & Hou, L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030558 · Cited by 136
High statistical heterogeneity is more frequent in meta-analysis of continuous than binary outcomes
Alba, A. C., Alexander, P. E., Chang, J., MacIsaac, J., DeFry, S., & Guyatt, G. H. (2016) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2015.09.005 · Cited by 129
“5 but the I 2 was nevertheless 0% [14].”
BackgroundWelikovitch, L. A., Do Carmo, S., Maglóczky, Z., Malcolm, J. C., Lőke, J., Klein, W. L., Freund, T., & Cuello, A. C. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1914593117 · Cited by 116
“Despite initial indications, clinical trials on the use of NSAIDs in already-diagnosed AD patients were found to be ineffective at slowing disease progression, and in some cases, even worsened clinical outcomes (6, 7).”
BackgroundAgosta, F., Dalla Libera, D., Spinelli, E. G., Finardi, A., Canu, E., Bergami, A., Bocchio Chiavetto, L., Baronio, M., Comi, G., Martino, G., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24235 · Cited by 113
Calsolaro, V., & Edison, P. (2015) · CNS Drugs · doi:10.1007/s40263-015-0301-8 · Cited by 93
Parsi, S., Smith, P. Y., Goupil, C., Dorval, V., & Hébert, S. S. (2015) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2015.33 · Cited by 83
Wattmo, C., Minthon, L., & Wallin, Å. K. (2016) · Alzheimer's Research & Therapy · doi:10.1186/s13195-016-0174-1 · Cited by 83
“However, a review of randomized trials found no effect of NSAID therapy on cognitive decline compared with placebo in patients with mild to moderate AD; however, none of the included studies was longer than 12 months [28].”
Chakrabarti, M., McDonald, A. J., Will Reed, J., Moss, M. A., Das, B. C., & Ray, S. K. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-150450 · Cited by 57
Stuve, O., Weideman, R. A., McMahan, D. M., Jacob, D. A., & Little, B. B. (2020) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756286420935676 · Cited by 40
Mullane, K., & Williams, M. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.09.027 · Cited by 32
Microglia as a cellular target of diclofenac therapy in Alzheimer’s disease
Stopschinski, B. E., Weideman, R. A., McMahan, D., Jacob, D. A., Little, B. B., Chiang, H.-S., Saez Calveras, N., & Stuve, O. (2023) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864231156674 · Cited by 26
The Dual Nature of Microglia in Alzheimer’s Disease: A Microglia-Neuron Crosstalk Perspective
Xie, Z., Meng, J., Wu, Z., Nakanishi, H., Hayashi, Y., Kong, W., Lan, F., Narengaowa, Yang, Q., Qing, H., et al. (2023) · The Neuroscientist · doi:10.1177/10738584211070273 · Cited by 19
Jamal, S., Goyal, S., Shanker, A., & Grover, A. (2015) · PLOS ONE · doi:10.1371/journal.pone.0129370 · Cited by 19
Metadata
- Authors
- Jaturapatporn, D., Isaac, M. G. E. K. N., McCleery, J., & Tabet, N.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2012-02-15
- Volume
- 2012
- Issue
- 2
- Pages
- CD006378-CD006378
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W2117324900
- Cited by
- 299
- References
- 133
- FWCI
- 18.11
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.